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State-of-the Art Lecture 1
Friday, July 15, 2011, 08:30 09:00
Meeting Room 309
SOTA1 Hospital Setting: Infection control in the
resistance era
W.-H. Seto*. WHO Collaborating Centre for Infection
Control, Hong Kong S.A.R.
In the hospital, for infection control, it is generally
recognized that it is easier to prevent the spread of
Gram-negative organisms as compared to the Gram positive
bacteria. A summary of the study by Lemmen et al,
JHI 2004:56:191 197 and data from Queen Mary Hospital
Hong Kong will be presented to support the concept. The
MDR Gram-negative organisms are now the focus of global
attention. A brief review of the different types and their
epidemiology in Asia will be presented. A two-tier system
for infection control of MDROs is generally recommended
as also by the CDC of USA. The system will be described.
In the second tier of preventive measures, the particular
measures must be selected based on the organism. In
terms of the newer Gram-negative MDROs, this can be
difﬁcult because the epidemiology of the organisms is still
not entirely clear. Furthermore the effectiveness of the
different microbiology methods such as for screening and
surveillance is not well deﬁned. Nevertheless an attempt
will be made to present the best possible strategies for
various Gram-negative organisms in the present context.
Concurrent Session 1: Hepatitis C Discovering
Genomics
Friday, July 15, 2011, 09:15 10:45
Meeting Room 310
CS1.1 HCV genotypes in hepatitis C patients and their
clinical signiﬁcances
J. Cheng*. Capital University Afﬁliated Beijing Ditan
Hospital, China
Abstract not available
CS1.2 Hepatitis C pharmacogenetics
G. Ahlenstiel *. Storr Liver Unit, Westmead Millennium
Institute, Westmead Hospital, University of Sydney,
Westmead, Australia
Traditionally, the candidate gene approach has been the
standard pharmacogenetic method to identify genetic
polymorphisms relevant for treatment response in human
disease. In 2009 this changed forever, when four
independent groups employed genome wide association
studies (GWAS) to examine the response to interferon-
alpha and ribavirin treatment of chronic hepatitis C virus
(HCV) genotype 1 infection. Importantly, all four studies
consistently identiﬁed polymorphisms in the interleukin 28B
(IL28B) gene, a lambda interferon, as a major determinant
of treatment outcomes. This represented a breakthrough for
our understanding of the pathogenesis of HCV infection and
in drug response for chronic hepatitis C. The studies have
identiﬁed IL28B as a pivotal molecule in these contexts and
explain to some degree the differences between ethnic
groups in treatment responses and the mechanisms for
spontaneous HCV clearance. More recent studies have
addressed the role of IL28B polymorphisms in the natural
history of HCV infection as well as in the context of HCV
genotype 2 and 3 disease and in liver transplantation. This
presentation is an update on the current understanding of
the role of IL28B in HCV infection as well as the role of
GWAS in HCV pharmacogenetics.
CS1.3 Genomic-based treatment paradigms for patients
with chronic hepatitis C infection
A.J. Thompson*. Head of Hepatology Research, St Vincent’s
Hospital, NHMRC Research Fellow, University of Melbourne,
Research Fellow, Victorian Infectious Diseases Reference
Laboratory (VIDRL) & Honorary Visiting Assistant Professor,
Duke University Medical Center, Melbourne, Australia
Abstract not available
CS1.4 Association of IL28B gene variations with
mathematical modeling of viral kinetics in
chronic hepatitis C patients
C.-S. Hsu1,2, D.-S. Chen2,3, J.-H. Kao2,3,4,5. 1Division
of Gastroenterology, Department of Internal Medicine,
Buddhist Tzu Chi General Hospital, Taipei Branch and
School of Medicine, Tzu Chi University, Hualien, Taiwan,
2Graduate Institute of Clinical Medicine, 3Department of
Internal Medicine, 4Department of Medical Research, and
5Hepatitis Research Center, National Taiwan University
College of Medicine and National Taiwan University
Hospital, Taipei, Taiwan
Background and Aims: Asian chronic hepatitis C (CHC)
patients are known to have better virologic responses to
pegylated interferon-based therapy than Western patients.
Although IL28B gene polymorphisms may contribute to
this difference, whether favorable hepatitis C virus (HCV)
kinetics during treatment also plays a role remains
unclear. Therefore, we conducted this study to explore the
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relationship between hepatitis C viral kinetics and IL28B
genotypes among Taiwanese CHC patients.
Methods: We enrolled 145 consecutive Taiwanese CHC
patients with pegylated interferon alfa-2a (Peg-IFN) plus
ribavirin for the study. Blood samples were taken more
frequently at deﬁned intervals in the ﬁrst 3 days. Pegylated
interferon alfa-2a (Peg-IFN) was administered weekly
together with daily ribavirin for 24 or 48 weeks according
to HCV genotypes. A new mathematical model was ﬁtted to
the observed HCV kinetics. In addition, the genomic DNAs of
91 patients who agreed to attend the host genomic survey
were obtained.
Results: A new mathematical model ﬁtted to the observed
HCV kinetics which could interpret the transient HCV titer
elevation after Peg-IFN treatment was constructed. The
results demonstrated a comparable viral clearance rate
(c = 3.45±3.73) (day 1, mean±SD) but lower daily viral
production rate (p = 106 1012) in our patients than that
reported before in Western patients. Of 110 patients with
sustained virologic response (SVR), 47 (43%) had a transient
elevation of viral titer within 12 hours (proportion of
12hours/3days, 44% in Non-SVR vs. 70% in SVR, p = 0.029).
Among 91 patients with available rs8099917 data, patients
with TT genotype had an early surge of viral titer after
therapy, higher SVR and viral clearance rate than those
with GT genotype.
Conclusions: Taiwanese CHC patients on Peg-IFN plus
ribavirin therapy have a lower daily viral production rate
than Western patients, and the rs8099917 TT genotype may
contribute to the increased viral clearance rate and better
virologic responses in these patients.
Concurrent Session 3: Invasive Fungal Infection
Friday, July 15, 2011, 09:15 10:45
Meeting Room 311B
CS3.1 Epidemiology and outcome of Candida
bloodstream infection in an intensive care unit in
Hong Kong
M. Hui *. Department of Microbiology, The Chinese
University of Hong Kong, Hong Kong, China
Candida albicans and Candida non-albicans are commonly
found as commensals in human body. However, they
are capable of producing life-threatening blood stream
infections. A retrospective review was undertaken to
analyze the characteristics of such infections in a single
centre intensive care unit. Emphasis was placed on
the demographics, risk factors, clinical manifestations,
complications as well as clinical outcome. In addition, the
distribution trend of different species of Candida was also
analyzed.
Our results revealed a high point prevalence of
candidaemia, and high crude mortality rate. Candida
albicans constituted half of all the cases, followed
by Candida tropicalis, Candida parapsilosis and Candida
glabrata. Age group analysis suggested that Candida
tropicalis outnumbered the other species in 10 19 years
old age group. An increasing trend of Candida glabrata was
observed with increasing age.
Our results suggested that early empirical antifungal should
be considered in high risk patients. The choice of antifungal
agents should cover the most likely Candida organisms in
the relevant age groups.
CS3.2 Efﬁcacy of common antifungal drugs
R.Y. Li *. Peking University First Hospital and Research
Center for Medical Mycology, Beijing, China
Abstract not available
CS3.3 Recent advances in management of cryptococcal
meningitis
T.C. Sorrell *. Sydney Institute for Emerging Infectious
Diseases and Biosecurity and Centre for Infectious Diseases
and Microbiology, Sydney Medical School Foundation
Fellow, Sydney Medical School, University of Sydney,
Westmead, Australia
Recent studies continue to highlight that there are
signiﬁcant clinical differences between infection due to
Cryptococcus neoformans and that due to its sibling species,
Cryptococcus gattii. There are emerging data suggesting
that molecular genetic types within each of the species
may also have different clinical presentations. Other species
dependent-differences include ecology, epidemiology and
host immune status. Neurological disease carries the highest
morbidity and mortality. Cryptococcal meningitis remains
a substantial health burden particularly in developing
countries, where it is associated with HIV infection
primarily. The major determinants of outcome include
neurological status, the level of intracranial pressure, the
presence of cerebral mass lesions and the cryptococcal load
in the CSF at presentation.
Antifungal treatment regimens should be guided by
host factors, severity of illness (including presence of
complications) and the causative cryptococcal species.
Recent clinical studies indicate the need for rapidly
fungicidal induction therapy regimens using amphotericin
B in combination with ﬂucytosine, to achieve optimal
outcomes. Maintenance therapy with ﬂuconazole is
necessary to prevent relapse and in the case of HIV
infection, until recovery of immune function. Cryptococcus
gattii meningitis requires prolonged induction/eradication
therapy. It is particularly important that prompt control of
raised intracranial pressure or hydrocephalus be achieved.
Clinicians should be vigilant for immune restoration like
features. Adjunctive surgery or corticosteroids may be
required to treat patients with large cryptococcomas,
cerebral oedema, or refractory infection.
The clinical relevance of isolates with relatively increased
minimum inhibitory concentrations of ﬂuconazole, that
have been observed in some small series of Cryptococcus
gattii infection, remains to be determined. Isolates of
Cryptococcus neoformans have remained susceptible to
ﬂuconazole, except where there has been widespread use
of ﬂuconazole as initial therapy for cryptococcal meningitis
in association with HIV.
CS3.4 Invasive fungal infections: Diagnosis and
treatments in China
Y.P. Ran*. Department of Dermatology, West China
Hospital, Sichuan University, China
The body location and clinical appearance of fungal
infections depends on the fungal virulence, infectious route
and host immunological state. The result being that patients
with mycoses consult with different clinical departments.
The diagnosis of mycoses is based on the detection of
fungal elements such as hyphae and/or yeast cells from the
involved tissues. Isolation of the fungus is the precondition
for species identiﬁcation and antifungal treatment. To think
clinically and to emphasize the mycology is the basic
consideration of medical mycology research. Working in
frontier of Translational Mycology, medical mycologists play
a key role in the collaboration between the aspects of
